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 Since radioiodine was first introduced in the therapy of hyperthyroidism in the 1940s, in the 21
st
 century, thyroid 
has become the arena of development of nuclear-molecular biology imaging. SPECT and PET technics allow the 
visualization of small particles like peptides and their receptors. In PET with 
18
F-FDG we can assess metabolic 
activity of thyroid tumours. If there is higher metabolic activity, the tumour is more aggressive and the prognosis 
poorer. These novel methods let us observe the primary lesion and metastatic processes in iodine avid 
differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC). Potentially, each particle triggered with 
a radioisotope which is involved in a cell structure and/or its metabolism can be useful in molecular imaging. The 
first group of molecules used in radioisotope molecular imaging is peptide receptors agonists and antagonists. 
Somatostatin receptors are overexpressed in DTC and MTC. Therefore, somatostatin analogues triggered with 










Lutetium) of these malignancies. Implementation of appropriate chelator allowed the creation of 
radiopharmaceuticals conjugated with either SPECT or PET isotopes. It seems that the best method for 
visualization of MTC is PET with 
18
F-DOPA up till now. Recently, new radiolabelled tracers for MTC 
visualizations are under investigation: cholecystokinin – 2 (CKK-2) gastrin receptor ligand radiolabelled with 
111
Indium and glucagon – like peptide -1 (GLP – 1) labelled with 99mTechnetium. 
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